Literature DB >> 16732997

Epstein-Barr virus and Hodgkin's lymphoma.

Jan Andersson1.   

Abstract

Hodgkin's lymphoma (HL) is a lymphoproliferative disorder of B-lymphocytes. Epstein-Barr virus (EBV) antigens can be detected in tumours in up to 40% of all HL cases. Patients with EBV-associated HL also show increased levels of EBV-infected B-lymphocytes in blood compared with normal individuals and non-EBV-associated HL cases. A peculiar pattern of restricted EBV-antigen expression, dominated by latent membrane protein-1 (LMP-1), LMP-2 and EBV nuclear antigen-1, is the characteristic feature of tumour-specific Hodgkin/Reed-Sternberg cells. This knowledge has generated studies examining adoptive immunotherapy of autologous or allogeneic cytotoxic T-cells for the treatment of refractory EBV-positive HL cases. Whether aborted EBV or another infectious aetiology is involved in non-EBV-associated HL cases remains an open question.

Entities:  

Mesh:

Year:  2006        PMID: 16732997

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  12 in total

1.  Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.

Authors:  Lee-Wen Chen; Vineetha Raghavan; Pey-Jium Chang; Duane Shedd; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  Virology       Date:  2009-02-15       Impact factor: 3.616

2.  Rhesus lymphocryptovirus type 1-associated B-cell nasal lymphoma in SIV-infected rhesus macaques.

Authors:  A K Marr-Belvin; A K Carville; M A Fahey; K Boisvert; S A Klumpp; M Ohashi; F Wang; S P O'Neil; S V Westmoreland
Journal:  Vet Pathol       Date:  2008-11       Impact factor: 2.221

3.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 4.  The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.

Authors:  Paolo De Paoli; Chiara Pratesi; Maria Teresa Bortolin
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

5.  HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection.

Authors:  Karen A McAulay; Craig D Higgins; Karen F Macsween; Annette Lake; Ruth F Jarrett; Faye L Robertson; Hilary Williams; Dorothy H Crawford
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  Comparative pathobiology of macaque lymphocryptoviruses.

Authors:  Angela Carville; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

7.  Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1.

Authors:  Caline G Matar; Udaya Shankari Rangaswamy; Brian S Wakeman; Neal Iwakoshi; Samuel H Speck
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

Review 8.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

Review 9.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

10.  EBV in Hodgkin Lymphoma.

Authors:  Giuseppina Massini; Doerte Siemer; Stefan Hohaus
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-11-24       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.